The decision was based on data from the Phase III AURORA 1 trial.
Cannabinoid receptors are currently the most popular targets for CNS in preclinical development, with 391 drugs tagged in total.
The current MS pipeline offers new hope for pre-progressive MS (PPMS) patients, with three late-stage agents in development.
KOLs interviewed by GlobalData have said Wegovy shows potential for the greatest amount of weight reduction in the obesity market.
Many healthcare companies are expected to prioritise AI as their main investment target over the next two years.
Get industry leading news, data and analysis delivered to your inbox
The Chinese pharma manufacturing industry is renowned for its generic active pharmaceutical ingredient (API) manufacturing.
The issues are expected to lead to quicker uptake of allogeneic cell therapies if these prove efficacious in long-term studies.
GlobalData believes that the implementation of these updated guidelines across the NHS will improve the diagnosis and surgical management of endometriosis.
Novo Nordisk has a strong T2D market presence due to the efficacy and strong performance of its therapies.
Approvals for innovator small molecules treating rare diseases in China rose by 22% from 2020 to 2022.